127 related articles for article (PubMed ID: 10410145)
21. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
[TBL] [Abstract][Full Text] [Related]
22. [Palliation of pain from bone metastases with radioactive isotopes].
Christensen TB; Petersen PM; Sørensen TH; Kamby C; Geertsen PF
Ugeskr Laeger; 2002 Jun; 164(23):3004-8. PubMed ID: 12082848
[TBL] [Abstract][Full Text] [Related]
23. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
Troncone L; Rufini V
Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.
Coover LR; Silberstein EB; Kuhn PJ; Graves MW
J Nucl Med; 2000 Nov; 41(11):1868-75. PubMed ID: 11079497
[TBL] [Abstract][Full Text] [Related]
25. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
26. Iodine-131-MIBG therapy of a patient with carcinoid liver metastases.
Prvulovich EM; Stein RC; Bomanji JB; Ledermann JA; Taylor I; Ell PJ
J Nucl Med; 1998 Oct; 39(10):1743-5. PubMed ID: 9776280
[TBL] [Abstract][Full Text] [Related]
27. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
Pasieka JL; McEwan AJ; Rorstad O
Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
Lopez-Penabad L; Chiu AC; Hoff AO; Schultz P; Gaztambide S; Ordoñez NG; Sherman SI
Cancer; 2003 Mar; 97(5):1186-94. PubMed ID: 12599224
[TBL] [Abstract][Full Text] [Related]
29. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer.
Doi SA; Woodhouse NJ
Clin Endocrinol (Oxf); 2000 Jun; 52(6):765-73. PubMed ID: 10848882
[TBL] [Abstract][Full Text] [Related]
30. Question of the month--January 1995. What is the optimal dose of 89Sr for bone pain palliation?
Khader Z
Nucl Med Commun; 1995 Apr; 16(4):306. PubMed ID: 7542759
[No Abstract] [Full Text] [Related]
31. [131I meta-iodobenzylguanidine in combination with hyperbaric oxygen therapy in the treatment of prognostically high-risk forms of neuroblastoma].
Stanková J; Kavan P; Krízová H; Hermanská E; Dosel P; Sázel M
Cas Lek Cesk; 2001 Jan; 140(1):13-7. PubMed ID: 11242978
[TBL] [Abstract][Full Text] [Related]
32. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
[TBL] [Abstract][Full Text] [Related]
33. Pain palliation with strontium-89 in children with metastatic disease.
Charron M; Brown M; Rowland P; Mirro J
Med Pediatr Oncol; 1996 Jun; 26(6):393-6. PubMed ID: 8614375
[TBL] [Abstract][Full Text] [Related]
34. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
35. Variation in oncologic opinion regarding management of metastatic bone pain with systemic radionuclide therapy.
Papatheofanis FJ
J Nucl Med; 1999 Sep; 40(9):1420-3. PubMed ID: 10492359
[TBL] [Abstract][Full Text] [Related]
36. Differentiated thyroid cancer: lobectomy and radioiodine, a treatment suitable for all cases?
Allan E; Owens SE; Waller ML
Nucl Med Commun; 1999 Nov; 20(11):983-9. PubMed ID: 10572907
[TBL] [Abstract][Full Text] [Related]
37. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
38. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman J; Onaitis MW; Tyler DS; Olson JA
Cancer; 2004 Nov; 101(9):1987-93. PubMed ID: 15455358
[TBL] [Abstract][Full Text] [Related]
39. Large remnant 131I ablation as an alternative to completion/total thyroidectomy in the treatment of well-differentiated thyroid cancer.
Leblanc G; Tabah R; Liberman M; Sampalis J; Younan R; How J
Surgery; 2004 Dec; 136(6):1275-80. PubMed ID: 15657587
[TBL] [Abstract][Full Text] [Related]
40. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
